DrugBiological
Panitumumab clinical trials
Also written ABX-EGF and E7.6.3.
- studies test it
- 196
- open now
- 24
- in phase 3
- 21
- first study started
- 2000
Keep track of what changes. Save the Panitumumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Panitumumab
- 139
- Vectibix
- 74
Studies by the year they started
193 studies that test it; most in 2010 (32)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2002 | 5 |
| 2003 | 3 |
| 2004 | 6 |
| 2005 | 2 |
| 2006 | 6 |
| 2007 | 10 |
| 2008 | 13 |
| 2009 | 19 |
| 2010 | 32 |
| 2011 | 17 |
| 2012 | 6 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 6 |
| 2016 | 7 |
| 2017 | 5 |
| 2018 | 10 |
| 2019 | 5 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 6 |
| 2025 | 4 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 42
- Phase 2
- 151
- Phase 3
- 21
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 48 · Other 148
Amgen (35) · M.D. Anderson Cancer Center (6) · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) (6) · Vejle Hospital (6) · UNICANCER (5) · Vanderbilt-Ingram Cancer Center (5) · AIO-Studien-gGmbH (5) · Grupo Espanol Multidisciplinario del Cancer Digestivo (5)
Often tested with
Tested in the same studies.
Irinotecan (20) · Oxaliplatin (16) · Fluorouracil (14) · Bevacizumab (12) · IRDye800 (11) · Capecitabine (10) · Carboplatin (9) · FOLFIRI Regimen (8)
Studies
Open first, then newest update. How each study uses Panitumumab is read from its arms, and is right about nine times in ten.
Testing it · 196
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerRecruitingPhase 2AbbVieNCT06820463Written as Panitumumab
- Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell CarcinomaRecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT07741643Written as Panitumumab-IRDye800
- Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical ProceduresRecruitingEarly Phase 1Eben RosenthalNCT07493447Written as Panitumumab-IRDye800
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Panitumumab
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT07318389Written as Panitumumab
- Dynamic Changes in Circulating Tumour Cells Protein ExpressionRecruitingPhase 2Matteo's FriendsNCT06314997Written as panitumumab (EGFR inhibitors)
- Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During SurgeryRecruitingPhase 1/2Stanford UniversityNCT03582124Written as Panitumumab-IRDye800
- Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical ProceduresRecruitingPhase 1/2Stanford UniversityNCT04085887Written as Panitumumab-IRDye800
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT05845450Written as Panitumumab
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationRecruitingPhase 3AmgenNCT06252649Written as Panitumumab
- Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck CancerRecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT06819228Written as Panitumumab IRDye 800
- A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C MutationRecruitingPhase 2AmgenNCT07172919Written as Panitumumab
- Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing SurgeryRecruitingPhase 1/2Stanford UniversityNCT03510208Written as Panitumumab
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS MutationsRecruitingPhase 3SWOG Cancer Research NetworkNCT06998940Written as Panitumumab
- (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell CarcinomaRecruitingPhase 1Eben RosenthalNCT05747625Written as Panitumumab
- A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRIRecruitingPhase 1R-PharmNCT07543744Written as RPH-030
- Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing SurgeryRecruitingPhase 1/2George PoultsidesNCT03384238Written as Panitumumab
- Evaluating 111In Panitumumab for Nodal Staging in Head and Neck CancerRecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT05901545Written as Panitumumab
- Phase II Panitumumab-IRDye800 in Head & Neck CancerRecruitingPhase 2University of Alabama at BirminghamNCT04511078Written as Panitumumab-IRDye800
- Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal CancerRecruitingPhase 2UNICANCERNCT06245356Written as Panitumumab
See all 196 studies that test Panitumumab →
Given in every arm · 27 — Panitumumab is usual care beside what is tested
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerRecruitingPhase 2Verastem, Inc.NCT07659795Written as panitumumab
- A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal AdenocarcinomaNot yet recruitingPhase 1Genentech, Inc.NCT07859085Written as Panitumumab
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesRecruitingPhase 1/2Institut de Recherches Internationales ServierNCT05786924Written as Panitumumab
- A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsRecruitingPhase 1Astellas Pharma IncNCT07094204Written as panitumumab
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT05863195Written as Panitumumab
- AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid TumorsRecruitingPhase 1AmgenNCT07094113Written as Panitumumab
- ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal CancerRecruitingPhase 2National Cancer Institute, NaplesNCT06714357Written as panitumumab
- Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the LiverRecruitingPhase 3Federation Francophone de Cancerologie DigestiveNCT02885753Written as Panitumumab
- Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the LiverCompletedPhase 2National Cancer Institute (NCI)NCT03366155Written as Panitumumab
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal CancerActive, not recruitingEarly Phase 1Roswell Park Cancer InstituteNCT06011772Written as Panitumumbab
- Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03087071Written as Panitumumab
- Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRCActive, not recruitingPhase 2University of Wisconsin, MadisonNCT04587128Written as Panitumumab
- Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal CancerActive, not recruitingPhase 2Australasian Gastro-Intestinal Trials GroupNCT05694936Written as Panitumumab
- Botensilimab and Balstilimab Optimization in Colorectal CancerActive, not recruitingPhase 2Nicholas DeVito, MDNCT06268015Written as Panitumumab
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingPhase 1AmgenNCT04185883Written as Panitumumab
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid TumorsTerminatedPhase 1Biosplice Therapeutics, Inc.NCT05084859Written as Panitumumab
- A Study of BBI608 in Adult Patients With Advanced Colorectal CancerCompletedPhase 2Sumitomo Pharma America, Inc.NCT01776307Written as Panitumumab
- First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTSCompletedPhase 3Gruppo Oncologico del Nord-OvestNCT03231722Written as Panitumumab
- Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck CancerCompletedPhase 2Eben RosenthalNCT03405142Written as Panitumumab-IRDye800
- 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus PanitumumabTerminatedPhase 3University of Southern CaliforniaNCT03300609Written as Panitumumab
Showing 20 of 27.
As the comparator · 5 — what is tested is compared with Panitumumab
- Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal CancerNot yet recruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT07829588Written as Vectibix®+ mFOLFOX6
- PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse SequenceCompletedPhase 2Gruppo Oncologico del Nord-OvestNCT04787341Written as Panitumumab
- 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCCWithdrawnPhase 2Andrei IagaruNCT05423197Written as Panitumumab
- Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic CancerCompletedPhase 2Federation Francophone de Cancerologie DigestiveNCT03186326Written as Panitumumab
- Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.Status unknownPhase 1Qilu Pharmaceutical Co., Ltd.NCT04234594Written as Vectibix®
Codes
What other systems call Panitumumab · ClinicalTrials.gg INT006741
- MeSH (NLM) D000077544PanitumumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6A901E312APANITUMUMABConfirmed FDA, NLM, Wikidata
- RxNorm 263034Confirmed FDA, Wikidata
- Wikidata Q417775panitumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1857PanitumumabOne source FDA
- DrugBank DB01269One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077544 | Panitumumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6A901E312A | PANITUMUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 263034 | — | Confirmed FDA, Wikidata |
| Wikidata | Q417775 | panitumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1857 | Panitumumab | One source FDA |
| DrugBank | DB01269 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.